Actuate Therapeutics, Inc.

ACTIVE

1751 River Run Ste 400, 德克萨斯州塔兰特县, Texas, United Stateswww.actuatetherapeutics.comPublic11–50 employeesEstablished: 2015-01-01+1 (817) 887-8455 info@actuatetherapeutics.com

Also known as:

actuate therapeutics, inc. (actuate)

2015-01-16

Part of bios capital management lp

Clinical Trials

4 active

Approvals

Total approvals

Agencies

Regulatory bodies

Founded

2015

Overview

Trial Phase Distribution

Phase

Trials

Phase 1

50.0%

Phase 2

37.5%

Trial Status Distribution

Active, not recruiting

37.5%

Completed

25.0%

Not yet recruiting

12.5%

Terminated

12.5%

Withdrawn

12.5%

Clinical Trials

Trials sponsored by this organization (8)

9-ING-41 Plus Carboplatin in Patients With Advanced, Metastatic Salivary Gland Carcinoma

Evaluate Preliminary Anti-tumor Activity of Elraglusib in Adult Participants With Advanced Solid Tumors

Phase 1

Not yet recruiting

interventional

Oct 2026100 participants

A clinical trial of a new drug known as 9-ING-41, that will take place inpatients with tumors or cancers that affect the blood and lymph system.9-ING-41 will be assessed as a standalone drug as well as being assessedwhen taken with chemotherapy drugs

Phase 1

Active, not recruiting

Feb 2023512 participants

Actuate 1901: 9-ING-41 in Myelofibrosis

Phase 2

Completed

interventional

Aug 202017 participants

9-ING-41 in Pediatric Patients With Refractory Malignancies.

Phase 1

Terminated

interventional

Jun 202040 participants

A clinical trial of a new drug known as 9-ING-41, that will take place inpatients with tumors or cancers that affect the blood and lymph system.9-ING-41 will be assessed as a standalone drug as well as being assessedwhen taken with chemotherapy drugs

Phase 1

Active, not recruiting

Oct 2019350 participants

9-ING-41 in Patients With Advanced Cancers

Phase 2

Active, not recruiting

interventional

Jan 2019350 participants

Actuate 1801: Phase 1/2 Study of 9-ING-41, a Glycogen Synthase Kinase-3 Beta (GSK-3β) Inhibitor, as a Single Agent and Combined with Chemotherapy, in Patients with Refractory Hematologic Malignancies or Solid Tumors

Completed

interventional

20 participants

Approvals

No approval data available

News

Elraglusib Granted FDA Rare Pediatric Disease Designation for Ewing Sarcoma

- Actuate Therapeutics' elraglusib, a GSK-3β inhibitor, receives FDA Rare Pediatric Disease Designation for Ewing sarcoma (EWS) treatment. - Early Phase 1/2 trial data shows promising anti-tumor activity, including durable complete responses in relapsed/refractory EWS patients. - The FDA designation may allow Actuate to receive a Priority Review Voucher upon NDA approval, potentially accelerating elraglusib's development. - Elraglusib is being evaluated in combination with topotecan/cyclophosphamide in a Phase 1/2 trial for pediatric patients with relapsed/refractory malignancies.

Nov 12, 2024

Back to Organizations

Actuate Therapeutics, Inc.

Overview

Trial Phase Distribution

Trial Status Distribution

Clinical Trials

Trials sponsored by this organization (8)

9-ING-41 Plus Carboplatin in Patients With Advanced, Metastatic Salivary Gland Carcinoma

Evaluate Preliminary Anti-tumor Activity of Elraglusib in Adult Participants With Advanced Solid Tumors

A clinical trial of a new drug known as 9-ING-41, that will take place inpatients with tumors or cancers that affect the blood and lymph system.9-ING-41 will be assessed as a standalone drug as well as being assessedwhen taken with chemotherapy drugs

Actuate 1901: 9-ING-41 in Myelofibrosis

9-ING-41 in Pediatric Patients With Refractory Malignancies.

A clinical trial of a new drug known as 9-ING-41, that will take place inpatients with tumors or cancers that affect the blood and lymph system.9-ING-41 will be assessed as a standalone drug as well as being assessedwhen taken with chemotherapy drugs

9-ING-41 in Patients With Advanced Cancers

Actuate 1801: Phase 1/2 Study of 9-ING-41, a Glycogen Synthase Kinase-3 Beta (GSK-3&beta;) Inhibitor, as a Single Agent and Combined with Chemotherapy, in Patients with Refractory Hematologic Malignancies or Solid Tumors

Approvals

News

Elraglusib Granted FDA Rare Pediatric Disease Designation for Ewing Sarcoma

Actuate 1801: Phase 1/2 Study of 9-ING-41, a Glycogen Synthase Kinase-3 Beta (GSK-3β) Inhibitor, as a Single Agent and Combined with Chemotherapy, in Patients with Refractory Hematologic Malignancies or Solid Tumors